Skip to main content
  • Clinical Update

    Are Medications Triggering Acute Angle Closure?

    By Rebecca Taylor, Contributing Writer, interviewing Anthony Kha­waja, MD, Ken Y. Lin, MD, PhD, and Thasarat S. Vajaranant, MD, MHA

    Download PDF

    How big a role do systemic medi­cations play in tipping a patient’s anatomically narrow angles into acute angle-closure (AAC) glaucoma? Various medications are associated with the onset of an AAC crisis. But quantify­ing the risk of individual drugs remains challenging, even with recent retrospec­tive studies on large, at-risk populations.

    Risks of Systemic Drugs

    Recent study flags problems. In a study published last year, Na and Park aimed to quantify the risk of various medications by analyzing insurance claims of more than 13,500 Koreans over several years.1 They identified 61 drugs statistically associated with AAC—out of a total of 949 drugs prescribed—and calculated the odds of developing AAC associated with each medication, expressed as an odds ratio (OR).

    The three drugs with the highest ORs were the antimigraine medication sumatriptan, the antiseizure medica­tion topiramate, and the antidepressant duloxetine (ORs, 12.6, 5.1, and 4.04, respectively). The study also identi­fied two drugs not previously on the “risky” list for AAC: lactulose, which is used for constipation (OR, 2.81), and metoclopramide, which is used to treat slow emptying of the stomach (OR, 2.52). For comparison, ORs for other common drugs that can trigger AAC were as follows: naproxen (3.49); the urinary drug propiverine (3.22); the respiratory drugs aminophylline (2.23) and mequitazine (2.02); alprazolam (1.59); and ibuprofen (1.57).

    Nondrug risk factors. Aside from the question of medications, other risk fac­tors for AAC are generally agreed upon. “For demographic risk factors we have advanced age, female sex, and Asian descent,” said Thasarat S. Vajaranant, MD, MHA, at the University of Illinois, Chicago. “For ocular risk factors, we have narrow angles, shallow anterior chamber, short axial length, hyperopia, and a history of glaucoma, especially prior ACC.”

    An eye with an acute closed angle.
    ACUTE CLOSED ANGLE. Acute angle-closure glaucoma carries a high risk of vision loss, given how quickly and how high IOP can rise.

    Two Proposed Mechanisms

    How, then, are demographic and ocular risk factors amplified by certain drugs?

    Medications associated with AAC work via two proposed mechanisms. “Either they have pupil dilation effects that trigger pupillary block, or they shift the lens-iris diaphragm forward in the so-called posterior-push mecha­nism,” said Ken Y. Lin, MD, PhD, at the University of California, Irvine.

    Pupillary dilation and block. Some drugs dilate the pupil through their an­ticholinergic effects, and that puts the pupil in a position where it maximally touches the lens, said Anthony Khawa­ja, MD, at Moorfields Eye Hospital in London. “This results in a buildup of aqueous fluid behind the iris, pushing it forward into acute angle closure.” Examples in this group of medica­tions include tricyclic antidepressants, antispasmodic drugs, and treatments for asthma (ipratropium bromide) and urinary incontinence (oxybutynin), Dr. Khawaja said. He added, “anything that dilates the pupil can tip people into acute angle closure.”

    Idiosyncratic effects. In addition, some medications have idiosyncratic effects that close the drainage angle in a variety of ways: they push the iris forward into the trabecular meshwork that normally drains the eye,1 possibly via edema, supraciliary effusions, or rotation of the ciliary body.2 “These idiosyncratic effects are not yet fully understood,” said Dr. Khawaja. “It’s probably a rare pharmacogenomic effect, where people are genetically pre­disposed to respond in this way.”

    Communication Is Essential

    The role of patient education. Reminding at-risk patients to watch for symptoms of AAC can help them know when urgent care is needed. “If patients have more than one symptom and it doesn’t resolve within an hour or so, they should seek urgent care,” said Dr. Khawaja. (Classic symp­toms—which typically are unilateral—include blurred vision, seeing haloes around lights, eye pain, temple pain, and headache, he noted.)

    Patients also should be educated about intermittent an­gle closure, which can present with intermittent headache or brow ache that often occurs in the evening, said Dr. Lin. These patients risk visual disability over time and should be warned about the symptoms and medications associat­ed with AAC, Dr. Vajaranant said.

    Working with other care providers. Collaboration among ophthalmology, primary care, and other prescribing providers could improve patient care, Dr. Vajaranant said.

    She called for ophthalmologists to review patients’ system­ic medications, “especially when classic symptoms of AAC are present.” And, she emphasized, if other providers are in doubt or if their patients have multiple risk factors for AAC, the risk of blindness mandates prompt referral to an ophthalmologist for screening and any needed treatment.

    Association Versus Causation

    Long lists of medications have been associated with angle closure, said Dr. Khawaja. The difficulty lies in differ­entiating “the list of drugs we think definitely do precipitate acute angle closure from those with less convincing evidence, which perhaps we don’t need to worry so much about,” he said.

    Not everyone agrees with case-cross­over study designs that mine large datasets. The Na and Park study, for instance, cast a particularly wide net, including a range of diagnostic codes without clear distinctions.2 High rates of polypharmacy—a patient taking five or more drugs simultaneously—further confounds assigning an objective risk for any one drug.3

    “I don’t think we can draw firm conclusions from observational associ­ation studies; they’re so susceptible to confounding and other biases,” said Dr. Khawaja.

    Medications of Concern

    Nonetheless, the experts agreed, there are medications of concern—and they noted that the decision of whether to advise patients against taking a given drug will depend on a risk/benefit anal­ysis for each patient.

    Anticholinergics. “The drugs we’re primarily concerned about are anticho­linergics like tricyclic antidepressants,” said Dr. Khawaja.

    “Anticholinergics are classic mydriatics, which can cause pupillary block and result in acute angle clo­sure,” said Dr. Lin. Common examples include drugs for chronic obstructive pulmonary disease, bladder conditions, and Parkinson disease.

    Cholinergics. Many cholinergics cause miosis and a forward shift of the lens; some also increase aqueous production and increase the blood flow to the ciliary body, said Dr. Lin. Common examples include drugs for dementia, post-op urinary retention, and open-angle glaucoma. Paradoxical­ly, some drugs that decrease the risk of open angle-closure glaucoma appear to increase the risk of AAC.3

    Sulfa drugs. “Sulfa drugs can cause angle closure by causing the ciliary body to rotate forward, so it pushes the lens-iris diaphragm forward,” said Dr. Lin. Common sulfa drugs, such as topiramate, are used for weight loss, migraine, headache, and seizures, he said.

    Antidepressants. While the tricy­clic antidepressants have long been associated with angle closure, said Dr. Khawaja, “I’m not convinced that SSRIs [selective serotonin reuptake inhibi­tors] precipitate acute angle closure.” As he pointed out, “Clinicians don’t all agree, but there isn’t a strong body of evidence that these drugs have a profound effect on the pupils. Oth­erwise, you’d have a lot more people complaining of blurred vision,” given the ubiquitous use of these drugs.

    Anticoagulants. While anticoagu­lants have been linked with AAC,3 it is unclear whether this is a direct or indirect result of their use, said Dr. Lin. “Anticoagulants can cause choroidal hemorrhages, and any significant hem­orrhage can lead to forward shifting of several anterior segment structures, which can trigger AAC.”

    OTC cold medications. “Over-the-counter flu and cold remedies or nasal decongestants contain the alpha-1 agonist, which has mild mydriatic ef­fects,” said Dr. Lin. “In patients with an occludable angle who haven’t had laser peripheral iridotomy, I remind them to stay away from these drugs, along with antihistamines.”

    Is There a Role for LPI?

    Dr. Lin recommends laser peripher­al iridotomy (LPI) for patients with occludable angles, but he noted that the conversation can be difficult, espe­cially when IOP is still within normal range and vision is good. “For the few patients who refuse LPI, I make sure to advise them to refrain from taking medications known to precipitate AAC,” he said.

    Others see the use of LPI changing. “The biggest thing we’ve learned is that the rate of developing acute angle closure after being diagnosed with these narrow drainage angles is smaller than we previously thought,” said Dr. Khawaja. “Most ophthalmologists have offered patients with narrow angles a laser iridotomy even if they didn’t have high intraocular pressure or signs of glaucoma, but the ZAP trial changed our thinking.”

    Impact of findings from ZAP. The ZAP trial in China focused on patients with anatomically narrow drainage angles but without high IOP or signs of glaucoma.4 Patients had one eye treated with peripheral laser iridotomy; the other eye was untreated. Patients were evaluated for 72 months for AAC, elevated IOP, or the synechiae that can precede angle closure. Of the 889 treated and 889 untreated eyes, only 19 treated eyes and 36 untreated eyes experienced one of these problems. The researchers concluded that the inci­dence of developing AAC was actually quite low—too low to warrant prophy­lactic laser iridotomy.

    That study was critical, said Dr. Khawaja, because it confirmed that “the rate of having acute angle closure after being diagnosed with these narrow an­gles is very low,” with or without laser treatment, he said. “Colleagues around the world are interpreting this study in different ways, but the big thing that’s changed is that a lot more patients aren’t getting laser,” he said.


    1 Na KI, Park SP. JAMA Ophthalmology. 2022;140(11):1055-1063.

    2 Foster PJ et al. JAMA Ophthalmology. 2022;140(11):1064-1065.

    3 Wu A et al. Eye. 2020;34(1):12-28.

    4 He M et al. Lancet. 2019;393(10191):1609-1618.


    Dr. Khawaja is a glaucoma specialist at Moor­fields Eye Hospital and associate professor at UCL Institute of Ophthalmology, both in London. Relevant financial disclosures: None.

    Dr. Lin is associate clinical professor of oph­thalmology and biomedical engineering, and the director of medical education in ophthal­mology at the Gavin Herbert Eye Institute at the University of California, Irvine. Relevant financial disclosures: None.

    Dr. Vajaranant is professor of ophthalmology, vice chair for Strategic Initiatives, and director of the glaucoma service at the Illinois Eye and Ear Infirmary at the University of Illinois, Chicago. Relevant financial disclosures: None.

    For full disclosures and the disclosure key, see below.

    Full Financial Disclosures

    Dr. Khawaja AbbVie: C; Aerie: C; Alcon: S; Google Health C; Heidelberg Engineering: L; Novartis, C; Reichert: C; Santen: C. Thea: L.

    Dr. Lin Alcon: C; Bausch + Lomb: C; MicroSurgical Technology: C; Zeiss: S.

    Dr. Vajaranant None.

    Disclosure Category



    Consultant/Advisor C Consultant fee, paid advisory boards, or fees for attending a meeting.
    Employee E Hired to work for compensation or received a W2 from a company.
    Employee, executive role EE Hired to work in an executive role for compensation or received a W2 from a company.
    Owner of company EO Ownership or controlling interest in a company, other than stock.
    Independent contractor I Contracted work, including contracted research.
    Lecture fees/Speakers bureau L Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    Patents/Royalty P Beneficiary of patents and/or royalties for intellectual property.
    Equity/Stock/Stock options holder, private corporation PS Equity ownership, stock and/or stock options in privately owned firms, excluding mutual funds.
    Grant support S Grant support or other financial support from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. Research funding should be disclosed by the principal or named investigator even if your institution receives the grant and manages the funds.
    Stock options, public or private corporation SO Stock options in a public or private company.
    Equity/Stock holder, public corporation US Equity ownership or stock in publicly traded firms, excluding mutual funds (listed on the stock exchange).